Uncovering the biology of multiple myeloma among African Americans

a comprehensive genomics approach.

Angela Baker, Esteban D Braggio, Susanna Jacobus, Sungwon Jung, Dirk Larson, Terry M Therneau, Angela Dispenzieri, Scott A. Van Wier, Gregory Ahmann, Joan Levy, Louise Perkins, Seungchan Kim, Kimberly Henderson, David Vesole, S Vincent Rajkumar, Diane F Jelinek, John Carpten, Rafael Fonseca

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Epidemiological data have suggested that African American (AA) persons are twice as likely to be diagnosed with multiple myeloma (MM) compared with European American (EA) persons. Here, we have analyzed a set of cytogenetic and genomic data derived from AA and EA MM patients. We have compared the frequency of IgH translocations in a series of data from 115 AA patients from 3 studies and 353 EA patients from the Eastern Cooperative Oncology Group (ECOG) studies E4A03 and E9487. We have also interrogated tumors from 45 AA and 196 EA MM patients for somatic copy number abnormalities associated with poor outcome. In addition, 35 AA and 178 EA patients were investigated for a transcriptional profile associated with high-risk disease. Overall, based on this cohort, genetic profiles were similar except for a significantly lower frequency of IgH translocations (40% vs 52%; P = .032) in AA patients. Frequency differences of somatic copy number aberrations were not significant after correction for multiple testing. There was also no significant difference in the frequency of high-risk disease based on gene expression profiling. Our study represents the first comprehensive comparisons of the frequency and distribution of molecular alterations in MM tumors between AA and EA patients. ECOG E4A03 is registered with ClinicalTrials.gov, number NCT00098475. ECOG E9487 is a companion validation set to the ECOG study E9486 and is registered with the National Institutes of Health, National Cancer Institute, Clinical Trials (PDQ), number EST-9486.

Original languageEnglish (US)
Pages (from-to)3147-3152
Number of pages6
JournalBlood
Volume121
Issue number16
DOIs
StatePublished - Apr 18 2013

Fingerprint

Oncology
Genomics
Multiple Myeloma
African Americans
Tumors
Aberrations
Gene expression
Health
National Cancer Institute (U.S.)
National Institutes of Health (U.S.)
Gene Expression Profiling
Cytogenetics
Testing
Neoplasms
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Uncovering the biology of multiple myeloma among African Americans : a comprehensive genomics approach. / Baker, Angela; Braggio, Esteban D; Jacobus, Susanna; Jung, Sungwon; Larson, Dirk; Therneau, Terry M; Dispenzieri, Angela; Van Wier, Scott A.; Ahmann, Gregory; Levy, Joan; Perkins, Louise; Kim, Seungchan; Henderson, Kimberly; Vesole, David; Rajkumar, S Vincent; Jelinek, Diane F; Carpten, John; Fonseca, Rafael.

In: Blood, Vol. 121, No. 16, 18.04.2013, p. 3147-3152.

Research output: Contribution to journalArticle

Baker, A, Braggio, ED, Jacobus, S, Jung, S, Larson, D, Therneau, TM, Dispenzieri, A, Van Wier, SA, Ahmann, G, Levy, J, Perkins, L, Kim, S, Henderson, K, Vesole, D, Rajkumar, SV, Jelinek, DF, Carpten, J & Fonseca, R 2013, 'Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.', Blood, vol. 121, no. 16, pp. 3147-3152. https://doi.org/10.1182/blood-2012-07-443606
Baker, Angela ; Braggio, Esteban D ; Jacobus, Susanna ; Jung, Sungwon ; Larson, Dirk ; Therneau, Terry M ; Dispenzieri, Angela ; Van Wier, Scott A. ; Ahmann, Gregory ; Levy, Joan ; Perkins, Louise ; Kim, Seungchan ; Henderson, Kimberly ; Vesole, David ; Rajkumar, S Vincent ; Jelinek, Diane F ; Carpten, John ; Fonseca, Rafael. / Uncovering the biology of multiple myeloma among African Americans : a comprehensive genomics approach. In: Blood. 2013 ; Vol. 121, No. 16. pp. 3147-3152.
@article{b53f91ae3efe4151bd3a8580092ce102,
title = "Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.",
abstract = "Epidemiological data have suggested that African American (AA) persons are twice as likely to be diagnosed with multiple myeloma (MM) compared with European American (EA) persons. Here, we have analyzed a set of cytogenetic and genomic data derived from AA and EA MM patients. We have compared the frequency of IgH translocations in a series of data from 115 AA patients from 3 studies and 353 EA patients from the Eastern Cooperative Oncology Group (ECOG) studies E4A03 and E9487. We have also interrogated tumors from 45 AA and 196 EA MM patients for somatic copy number abnormalities associated with poor outcome. In addition, 35 AA and 178 EA patients were investigated for a transcriptional profile associated with high-risk disease. Overall, based on this cohort, genetic profiles were similar except for a significantly lower frequency of IgH translocations (40{\%} vs 52{\%}; P = .032) in AA patients. Frequency differences of somatic copy number aberrations were not significant after correction for multiple testing. There was also no significant difference in the frequency of high-risk disease based on gene expression profiling. Our study represents the first comprehensive comparisons of the frequency and distribution of molecular alterations in MM tumors between AA and EA patients. ECOG E4A03 is registered with ClinicalTrials.gov, number NCT00098475. ECOG E9487 is a companion validation set to the ECOG study E9486 and is registered with the National Institutes of Health, National Cancer Institute, Clinical Trials (PDQ), number EST-9486.",
author = "Angela Baker and Braggio, {Esteban D} and Susanna Jacobus and Sungwon Jung and Dirk Larson and Therneau, {Terry M} and Angela Dispenzieri and {Van Wier}, {Scott A.} and Gregory Ahmann and Joan Levy and Louise Perkins and Seungchan Kim and Kimberly Henderson and David Vesole and Rajkumar, {S Vincent} and Jelinek, {Diane F} and John Carpten and Rafael Fonseca",
year = "2013",
month = "4",
day = "18",
doi = "10.1182/blood-2012-07-443606",
language = "English (US)",
volume = "121",
pages = "3147--3152",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Uncovering the biology of multiple myeloma among African Americans

T2 - a comprehensive genomics approach.

AU - Baker, Angela

AU - Braggio, Esteban D

AU - Jacobus, Susanna

AU - Jung, Sungwon

AU - Larson, Dirk

AU - Therneau, Terry M

AU - Dispenzieri, Angela

AU - Van Wier, Scott A.

AU - Ahmann, Gregory

AU - Levy, Joan

AU - Perkins, Louise

AU - Kim, Seungchan

AU - Henderson, Kimberly

AU - Vesole, David

AU - Rajkumar, S Vincent

AU - Jelinek, Diane F

AU - Carpten, John

AU - Fonseca, Rafael

PY - 2013/4/18

Y1 - 2013/4/18

N2 - Epidemiological data have suggested that African American (AA) persons are twice as likely to be diagnosed with multiple myeloma (MM) compared with European American (EA) persons. Here, we have analyzed a set of cytogenetic and genomic data derived from AA and EA MM patients. We have compared the frequency of IgH translocations in a series of data from 115 AA patients from 3 studies and 353 EA patients from the Eastern Cooperative Oncology Group (ECOG) studies E4A03 and E9487. We have also interrogated tumors from 45 AA and 196 EA MM patients for somatic copy number abnormalities associated with poor outcome. In addition, 35 AA and 178 EA patients were investigated for a transcriptional profile associated with high-risk disease. Overall, based on this cohort, genetic profiles were similar except for a significantly lower frequency of IgH translocations (40% vs 52%; P = .032) in AA patients. Frequency differences of somatic copy number aberrations were not significant after correction for multiple testing. There was also no significant difference in the frequency of high-risk disease based on gene expression profiling. Our study represents the first comprehensive comparisons of the frequency and distribution of molecular alterations in MM tumors between AA and EA patients. ECOG E4A03 is registered with ClinicalTrials.gov, number NCT00098475. ECOG E9487 is a companion validation set to the ECOG study E9486 and is registered with the National Institutes of Health, National Cancer Institute, Clinical Trials (PDQ), number EST-9486.

AB - Epidemiological data have suggested that African American (AA) persons are twice as likely to be diagnosed with multiple myeloma (MM) compared with European American (EA) persons. Here, we have analyzed a set of cytogenetic and genomic data derived from AA and EA MM patients. We have compared the frequency of IgH translocations in a series of data from 115 AA patients from 3 studies and 353 EA patients from the Eastern Cooperative Oncology Group (ECOG) studies E4A03 and E9487. We have also interrogated tumors from 45 AA and 196 EA MM patients for somatic copy number abnormalities associated with poor outcome. In addition, 35 AA and 178 EA patients were investigated for a transcriptional profile associated with high-risk disease. Overall, based on this cohort, genetic profiles were similar except for a significantly lower frequency of IgH translocations (40% vs 52%; P = .032) in AA patients. Frequency differences of somatic copy number aberrations were not significant after correction for multiple testing. There was also no significant difference in the frequency of high-risk disease based on gene expression profiling. Our study represents the first comprehensive comparisons of the frequency and distribution of molecular alterations in MM tumors between AA and EA patients. ECOG E4A03 is registered with ClinicalTrials.gov, number NCT00098475. ECOG E9487 is a companion validation set to the ECOG study E9486 and is registered with the National Institutes of Health, National Cancer Institute, Clinical Trials (PDQ), number EST-9486.

UR - http://www.scopus.com/inward/record.url?scp=84879144365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879144365&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-07-443606

DO - 10.1182/blood-2012-07-443606

M3 - Article

VL - 121

SP - 3147

EP - 3152

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -